Dystrophic Epidermolysis Bullosa Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Phoenicis, Aegle, Anterogen, Abeona, Eloxx

 Breaking News
  • No posts were found

Dystrophic Epidermolysis Bullosa Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Phoenicis, Aegle, Anterogen, Abeona, Eloxx

November 07
21:42 2023
Dystrophic Epidermolysis Bullosa Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Phoenicis, Aegle, Anterogen, Abeona, Eloxx
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Dystrophic Epidermolysis Bullosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Dystrophic Epidermolysis Bullosa Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dystrophic Epidermolysis Bullosa Market. 

The Dystrophic Epidermolysis Bullosa Pipeline report embraces in-depth commercial, regulatory, and Dystrophic Epidermolysis Bullosa clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Dystrophic Epidermolysis Bullosa drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dystrophic Epidermolysis Bullosa Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Dystrophic Epidermolysis Bullosa treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Dystrophic Epidermolysis Bullosa therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Dystrophic Epidermolysis Bullosa companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Dystrophic Epidermolysis Bullosa drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dystrophic Epidermolysis Bullosa therapeutic market.

Dystrophic Epidermolysis Bullosa Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Dystrophic Epidermolysis Bullosa. Currently, Castle Creek Biosciences is leading the therapeutics market with its Dystrophic Epidermolysis Bullosa drug candidates in the most advanced stage of clinical development.

Dystrophic Epidermolysis Bullosa Companies Actively Working in the Therapeutic Market Include:

  • Phoenix Tissue Repair

  • Castle Creek Biosciences

  • Phoenicis Therapeutics

  • Aegle Therapeutics

  • RHEACELL GmbH & Co. KG

  • Anterogen Co., Ltd.

  • Abeona Therapeutics, Inc

  • InMed Pharmaceuticals

  • BridgeBio Inc.

  • Eloxx Pharmaceuticals

  • Relief Therapeutics

  • Quoin Pharmaceuticals

And Many Others

Emerging and Marketed Dystrophic Epidermolysis Bullosa Drugs Covered in the Report Include:

  • TR-01: Phoenix Tissue Repair

  • FCX-007: Castle Creek Biosciences

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Dystrophic Epidermolysis Bullosa Companies Working in the Market @


Analysis of Emerging Dystrophic Epidermolysis Bullosa Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

​​Dystrophic Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Dystrophic Epidermolysis Bullosa Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Dystrophic Epidermolysis Bullosa Treatment Patterns

4. Dystrophic Epidermolysis Bullosa – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dystrophic Epidermolysis Bullosa Late Stage Products (Phase-III)

7. Dystrophic Epidermolysis Bullosa Mid-Stage Products (Phase-II)

8. Dystrophic Epidermolysis Bullosa Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dystrophic Epidermolysis Bullosa Discontinued Products

13. Dystrophic Epidermolysis Bullosa Product Profiles

14. Major Dystrophic Epidermolysis Bullosa Companies in the Market

15. Key Products in the Dystrophic Epidermolysis Bullosa Therapeutics Segment

16. Dormant and Discontinued Products

17. Dystrophic Epidermolysis Bullosa Unmet Needs

18. Dystrophic Epidermolysis Bullosa Future Perspectives

19. Dystrophic Epidermolysis Bullosa Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Charcot-Marie-Tooth Disease Market

“Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Charcot-Marie-Tooth Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Related Articles


December 2023